Table 3.
Subjects with adverse events
| Treatment emergent adverse events | ||||
|---|---|---|---|---|
| Pegfilgrastim group n = 54 | Filgrastim group n = 55 | |||
| n | (%) | n | (%) | |
| Overall | 54 | 100 | 55 | 100 |
| Platelet count decreased | 53 | 98·1 | 55 | 100 |
| Neutrophil count decreased | 52 | 96·3 | 55 | 100 |
| Haemoglobin decreased | 23 | 42·6 | 25 | 45·5 |
| Febrile neutropenia | 20 | 37·0 | 12 | 21·8 |
| Back pain | 12 | 22·2 | 16 | 29·1 |
| Pyrexia | 12 | 22·2 | 14 | 25·5 |
| Blood lactate dehydrogenase increased | 11 | 20·4 | 18 | 32·7 |
| Malaise | 10 | 18·5 | 5 | 9·1 |
| Nausea | 8 | 14·8 | 7 | 12·7 |
| Stomatitis | 8 | 14·8 | 8 | 14·5 |
| Vomiting | 8 | 14·8 | 1 | 1·8 |
| Decreased appetite | 8 | 14·8 | 4 | 7·3 |
| Urticaria | 6 | 11·1 | 5 | 9·1 |
| Alopecia | 5 | 9·3 | 8 | 14·5 |
| Headache | 5 | 9·3 | 6 | 10·9 |
| Blood alkaline phosphatase increased | 3 | 5·6 | 7 | 12·7 |